The UK is a step closer to having the first approved treatment for EB patients, following yesterday’s announcement from Amryt Pharma that their Filsuvez® gel has been approved by the European Commission for the treatment of Dystrophic EB and Junctional EB.

Filsuvez® gel is applied to the skin and contains birch bark extract, which is rich in a compound called Betulin which, research suggests, can activate skin cells, and regulate the inflammatory response involved in wound healing. The benefit of Filsuvez® is its ability to promote healing of partial thickness wounds.

It is hoped that following approval by the European Commission, the UK’s MHRA (Medicines and Healthcare Products Regulatory Agency) will follow suit and approve Filsuvez® for use in the UK by the end of year.

Read the full update from Amryt